Leerink Partners analyst Thomas J. Smith reiterated an Outperform rating on Spyre (NASDAQ: SYRE).The analyst comments "SYRE (OP) announced positive ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Hot Comments

TD Cowen on Spyre (SYRE): 'we expect these data to further raise the ceiling for Spyre's future combos'April 13, 2026 7:57 AM Mizuho on Spyre (SYRE): 'We see these results as an extremely favorable outcome'April 13, 2026 7:54 AM Form 8-K Spyre Therapeutics, Inc. For: Apr 13April 13, 2026 7:47 AM Guggenheim on Top Pick Spyre (SYRE): 'We expect the stock could be up >40% on today's news'April 13, 2026 7:46 AM Spyre reports positive trial results for ulcerative colitis drug SPY001April 13, 2026 7:00 AM Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis PatientsApril 13, 2026 7:00 AM Spyre Therapeutics (SYRE) Halted, News PendingApril 13, 2026 6:56 AM Form ARS Spyre Therapeutics, Inc. For: Dec 31April 10, 2026 4:14 PM Form DEFA14A Spyre Therapeutics, Inc. April 10, 2026 4:05 PM Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026April 10, 2026 4:05 PM Form DEF 14A Spyre Therapeutics, Inc. For: May 27April 10, 2026 4:02 PM